Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction
Wei‐Ren Chen, Xueqin Shen, Ying Zhang, et al.
Endocrine (2015) Vol. 52, Iss. 3, pp. 516-526
Closed Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck, Juris J. Meier, Matthew A. Cavender, et al.
Circulation (2017) Vol. 136, Iss. 9, pp. 849-870
Open Access | Times Cited: 498
Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial
Anders Jorsal, Caroline Kistorp, Pernille Holmager, et al.
European Journal of Heart Failure (2016) Vol. 19, Iss. 1, pp. 69-77
Open Access | Times Cited: 425
Protective role of melatonin in cardiac ischemia‐reperfusion injury: From pathogenesis to targeted therapy
Hao Zhou, Qiang Ma, Pingjun Zhu, et al.
Journal of Pineal Research (2018) Vol. 64, Iss. 3
Open Access | Times Cited: 219
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 215
Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca2+–XO–ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways
Ying Zhang, Hao Zhou, Wenbo Wu, et al.
Free Radical Biology and Medicine (2016) Vol. 95, pp. 278-292
Closed Access | Times Cited: 175
BI1 is associated with microvascular protection in cardiac ischemia reperfusion injury via repressing Syk–Nox2–Drp1-mitochondrial fission pathways
Hao Zhou, Shi Chen, Shunying Hu, et al.
Angiogenesis (2018) Vol. 21, Iss. 3, pp. 599-615
Closed Access | Times Cited: 163
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 25
Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells
Ao Chen, Zhangwei Chen, Yan Xia, et al.
Biochemical and Biophysical Research Communications (2018) Vol. 499, Iss. 2, pp. 267-272
Closed Access | Times Cited: 94
Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
Niki Katsiki, Ele Ferrannini
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 12, pp. 107723-107723
Open Access | Times Cited: 78
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
Johanna Helmstädter, Karin Keppeler, Leonie Küster, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 659-676
Open Access | Times Cited: 56
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
Frederick Berro Rivera, Grace Nooriza O. Lumbang, Danielle Rose Magno Gaid, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2209-2228
Open Access | Times Cited: 15
Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence
Paschalis Karakasis, Dimitrios Patoulias, George Kassimis, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 27, pp. 2109-2119
Closed Access | Times Cited: 8
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway
Huiying Qiao, Haiyan Ren, He Du, et al.
Molecular Medicine Reports (2018)
Open Access | Times Cited: 78
GLP-1 receptor agonists and heart failure in diabetes
André Scheen
Diabetes & Metabolism (2017) Vol. 43, pp. 2S13-2S19
Open Access | Times Cited: 63
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Franco Arturi, Elena Succurro, Sofia Miceli, et al.
Endocrine (2016) Vol. 57, Iss. 3, pp. 464-473
Closed Access | Times Cited: 62
Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Huixing Liu, Di Fu, Daoquan Peng
Clinical Therapeutics (2023) Vol. 45, Iss. 1, pp. 17-30
Open Access | Times Cited: 18
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
Preman Kumarathurai, Christian Anholm, Olav Wendelboe Nielsen, et al.
Cardiovascular Diabetology (2016) Vol. 15, Iss. 1
Open Access | Times Cited: 52
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Dapeng Zhang, Li Xu, Lefeng Wang, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 45
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Mario Schubert, Sinah Hansen, Julian Leefmann, et al.
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 42
Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives
Alessandro Bellis, Ciro Mauro, Emanuele Barbato, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 775-775
Open Access | Times Cited: 39
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Dan Xu, Ankith Nair, Charlie Sigston, et al.
Cardiovascular Therapeutics (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 26
The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis
Nooraldin Merza, Moeez Akram, Aqsa Mengal, et al.
Current Problems in Cardiology (2023) Vol. 48, Iss. 5, pp. 101602-101602
Closed Access | Times Cited: 14
Endothelial progenitor cells (EPCs) in ageing and age-related diseases: How currently available treatment modalities affect EPC biology, atherosclerosis, and cardiovascular outcomes
Velimir Altabas, Velimir Altabas, Lora Kirigin
Mechanisms of Ageing and Development (2016) Vol. 159, pp. 49-62
Closed Access | Times Cited: 45
Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction
Wei Ren Chen, Feng Tian, Yun Dai Chen, et al.
International Journal of Cardiology (2015) Vol. 208, pp. 109-114
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top